Management of Grade B Esophagitis with Forrest III Duodenal Ulcer and Positive H. pylori
This patient requires immediate initiation of H. pylori eradication therapy with standard triple therapy (PPI, amoxicillin, clarithromycin) for 14 days, preceded by 72-96 hours of intravenous PPI, followed by long-term maintenance PPI therapy for the Grade B esophagitis. 1
Immediate Management Algorithm
Step 1: Initiate High-Dose PPI Therapy
- Start intravenous PPI for 72-96 hours before beginning H. pylori eradication 1
- This addresses both the esophagitis and prepares for optimal H. pylori treatment
Step 2: H. pylori Eradication (Critical for Preventing Ulcer Recurrence)
The rapid urease test (RUT) positivity confirms active H. pylori infection, which is directly responsible for the duodenal ulcer and carries a 26% rebleeding rate if left untreated 1. The Forrest III classification indicates a clean-based ulcer with low immediate bleeding risk, but eradication is mandatory to prevent recurrence.
First-line regimen (if local clarithromycin resistance <15%):
- PPI standard dose twice daily
- Amoxicillin 1000 mg twice daily
- Clarithromycin 500 mg twice daily
- Duration: 14 days 1
Alternative if high clarithromycin resistance suspected:
- 10-day sequential therapy with amoxicillin, clarithromycin, metronidazole, and PPI 1
If first-line fails:
- 10-day levofloxacin-amoxicillin triple therapy 1
Step 3: Long-Term Acid Suppression for Esophagitis
Grade B esophagitis requires indefinite maintenance PPI therapy - this is non-negotiable 2. After completing H. pylori eradication:
- Continue single-dose PPI daily indefinitely
- Do NOT attempt to wean off therapy, as Grade B esophagitis (Los Angeles B or greater) mandates long-term acid suppression 2
Critical Pitfalls to Avoid
Do NOT use empirical antibiotics without confirming H. pylori status - the guidelines explicitly recommend against this approach 1. Your positive RUT confirms infection, so proceed directly to eradication.
Do NOT stop PPI therapy after ulcer healing - the Grade B esophagitis independently requires continuous acid suppression regardless of ulcer status 2. Patients often mistakenly discontinue PPIs after symptom resolution, leading to esophagitis recurrence.
Be aware of potential GERD worsening post-eradication - approximately 26% of duodenal ulcer patients develop new or worsened reflux esophagitis after H. pylori cure 3. Your patient already has Grade B esophagitis, making continued PPI therapy even more critical.
Follow-Up Strategy
At 6-8 weeks post-treatment:
- Confirm H. pylori eradication with urea breath test or stool antigen test (NOT rapid urease test, as PPIs cause false negatives) 4
- If still symptomatic, consider repeat endoscopy to assess ulcer healing and esophagitis status
- If eradication fails, obtain culture and susceptibility testing before second-line therapy 4
Long-term management:
- Maintain daily PPI indefinitely for Grade B esophagitis 2
- Counsel on lifestyle modifications (weight management, dietary triggers, head-of-bed elevation)
- Monitor for symptom recurrence suggesting treatment failure
Evidence Strength and Rationale
The 2020 WSES guidelines provide the strongest evidence base for H. pylori management in peptic ulcer disease 1. The recommendation for 72-96 hours of IV PPI before starting triple therapy is a strong recommendation despite low-quality evidence, reflecting expert consensus on optimal timing. The requirement for long-term PPI in Grade B esophagitis comes from the 2022 AGA guidelines on GERD management 2, which explicitly state that Los Angeles B or greater esophagitis requires indefinite acid suppression.
The dual pathology here (ulcer + esophagitis) creates a unique situation where both conditions benefit from PPI therapy, but the H. pylori eradication is essential to prevent ulcer recurrence while the PPI addresses both conditions simultaneously.